Indian subsidiary of Merck Sharp and Dohme (MSD), a drug firm has decided to enter into voluntary licensing agreements for investigational oral antiviral drug candidate ‘molnupiravir’, it said on Tuesday.
The drug is being studied for the treatment of Covid-19 with Indian firms Sun Pharma, Cipla, Dr Reddy’s, Emcure Pharma and Hetero Labs.
Molnupiravir is currently being studied in a Phase 3 trial for treatment of non-hospitalized patients with confirmed Covid-19, MSD India said in a statement.
